Blog
KP-RT3: Research Overview
KP-RT3 is a laboratory research designation for a synthetic peptide compound class studied for its engagement with multiple metabolic hormone receptor pathways, including receptors involved in glucose-dependent insulinotropic signaling, incretin signaling, and glucagon receptor signaling.
A phase 2, double-blind, randomized, placebo-controlled trial published in the New England Journal of Medicine (2023) examined this multi-receptor-agonist peptide class in 338 human adults with obesity or overweight plus a weight-related condition, using once-weekly subcutaneous administration over 48 weeks; the study reported dose-related changes in body weight measurements over the study period, along with gastrointestinal and cardiovascular parameters monitored as part of the trial (PubMed).
A related phase 2a randomized, double-blind, placebo-controlled substudy published in Nature Medicine (2024) examined this peptide class in 98 human participants with obesity and metabolic dysfunction-associated steatotic liver disease, using MRI-based liver fat quantification and metabolic biomarkers over 48 weeks; dose-related changes in liver-fat measurements were reported, associated with changes in body weight, abdominal adipose tissue, and insulin sensitivity in the model examined; the study noted it did not include liver histology or participants with advanced fibrosis or cirrhosis (PMC).
For laboratory research use only — not for human consumption. This content is presented for educational and informational purposes and is not intended as medical advice, a treatment claim, or usage instruction.
